NEXLIZET: payments to doctors
Payments that named NEXLIZET as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $10.3M
- Providers
- 11,586
- Transactions
- 25,071
- Average per transaction
- $410
The per-transaction average — $410 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 11,586 providers the average total is $887, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Esperion Therapeutics, Inc. | $10,251,085 | 99.7% |
| Currax Pharmaceuticals LLC | $29,402 | 0.3% |